<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nmp</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Sklifosovsky Journal "Emergency Medical Care"</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2223-9022</issn><issn pub-type="epub">2541-8017</issn><publisher><publisher-name>“N.V. Sklifosovsky Research Institute for Emergency Medicine”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23934/2223-9022-2021-10-4-669-675</article-id><article-id custom-type="elpub" pub-id-type="custom">nmp-1266</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Маркеры развития рестеноза зоны реконструкции после эндоваскулярных вмешательств на артериях нижних конечностей</article-title><trans-title-group xml:lang="en"><trans-title>Markers of the Development of the Reconstruction Area Restenosis After Endovascular Interventions in Lower Limbs Arteries</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0817-9573</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калинин</surname><given-names>Р. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalinin</surname><given-names>R. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой сердечно-сосудистой,  рентгенэндоваскулярной, оперативной хирургии и топографической анатомии,</p><p>390026, Рязань, ул. Высоковольтная, д. 9</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor, Head of the Department of Cardiovascular, X-ray Endovascular, Operative Surgeryand Topographic Anatomy,</p><p>9 Vysokovoltnaya St., Ryazan, 390026</p></bio><email xlink:type="simple">kalinin-re@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1292-5452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сучков</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Suchkov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, профессор кафедры сердечно-сосудистой, рентгенэндоваскулярной, оперативной хирургии и топографической анатомии,</p><p>390026, Рязань, ул. Высоковольтная, д. 9</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor, Professor of the Department of Cardiovascular, X-ray Endovascular, OperativeSurgery and Topographic Anatomy,</p><p>9 Vysokovoltnaya St., Ryazan, 390026</p></bio><email xlink:type="simple">suchkov_med@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4855-9068</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климентова</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimentova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, соискатель кафедры сердечно-сосудистой, рентгенэндоваскулярной, оперативной хирургии и топографической анатомии,</p><p>390026, Рязань, ул. Высоковольтная, д. 9</p></bio><bio xml:lang="en"><p>Candidate of Medical Sciences, Applicant of the Department of Cardiovascular, X-ray Endovascular, Operative Surgery andTopographic Anatomy,</p><p>9 Vysokovoltnaya St., Ryazan, 390026</p></bio><email xlink:type="simple">klimentowa.emma@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1688-0017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щулькин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchulkin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры фармакологии с курсом фармации факультета дополнительного профессионального образования,</p><p>390026, Рязань, ул. Высоковольтная, д. 9</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor of the Department of Pharmacology with a course in Pharmacy at the Faculty ofAdditional Professional Education,</p><p>9 Vysokovoltnaya St., Ryazan, 390026</p></bio><email xlink:type="simple">alekseyshulkin@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Рязанский государственный медицинский университет им. акад. И.П. Павлова» МЗ РФ<country>Россия</country></aff><aff xml:lang="en">I.P. Pavlov Ryazan State Medical University of Ministry of Health of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>01</month><year>2022</year></pub-date><volume>10</volume><issue>4</issue><fpage>669</fpage><lpage>675</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калинин Р.Е., Сучков И.А., Климентова Э.А., Щулькин А.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Калинин Р.Е., Сучков И.А., Климентова Э.А., Щулькин А.В.</copyright-holder><copyright-holder xml:lang="en">Kalinin R.E., Suchkov I.A., Klimentova E.A., Shchulkin A.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jnmp.ru/jour/article/view/1266">https://www.jnmp.ru/jour/article/view/1266</self-uri><abstract><p>Рестеноз зоны реконструкции является одним из основных послеоперационных осложнений оперативных вмешательств на артериях нижних конечностей, который развивается в 18–40% случаев и ведет к развитию тромбоза зоны реконструкции и увеличению риска потери конечности до 20–25%. Поиск новых маркеров прогнозирования развития данного осложнения у пациентов с облитерирующим атеросклерозом артерий нижних конечностей (ОААНК) является актуальной проблемой на сегодняшний день.</p><sec><title>Цель исследования</title><p>Цель исследования. Оценка динамики маркеров апоптоза и пролиферации клеток в различные сроки после эндоваскулярного вмешательства и их роль в развитии рестеноза зоны реконструкции у пациентов с ОААНК.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 30 пациентов с ОААНК с III стадией заболевания. После дообследования пациентам было выполнено эндоваскулярное вмешательство на артериях бедренно-подколенного сегмента. В случае развития рестеноза зоны вмешательства пациенты были повторно оперированы. У пациентов до операции в первый час, а затем на 1-е, 7-е, 14-е, 21-е, 30-е сутки после операции была взята венозная кровь для определения маркеров Вах, sFas, PDGF BB с помощь иммуноферментного анализа.</p></sec><sec><title>Результаты</title><p>Результаты. После эндоваскулярного вмешательства происходил запуск первой волны апоптоза с повышением в крови количества белка Вах (р=0,00003) с 1 по 24 часа с его последующим снижением к 7-м суткам (р=0,0008) по сравнению с количеством на 1-е сутки. Уровень PDGF BB возрастал с 1-х суток после операции (р=0,03) с максимальными значениями на 7-е сутки (р=0,0002) по сравнению с уровнем на 1-е сутки. Затем происходил запуск второй волны с пиковым снижением уровня ингибитора апоптоза sFas на 21-е сутки (р=0,002). У 10 пациентов через 9–12 месяцев развился рестеноз зоны вмешательства с возвратом ишемии конечности. В первый час (р=0,004) у пациентов с рестенозом был статистически значимо повышен уровень белка Вах, при повышении PDGF ВВ на 7-е сутки (р=0,011), а sFas на 21-е сутки (р=0,0001), PDGF ВВ к концу 1-го месяца (р=0,004) по сравнению со значениями у пациентов без данного осложнения.</p></sec><sec><title>Выводы</title><p>Выводы. 1. Эндоваскулярное вмешательство вызывает две волны апоптоза в послеоперационном периоде. Первая волна связана с повышением содержания белка Вах в первые часы с последующим увеличением PDGF ВВ на 7-е сутки. Вторая волна апоптоза обусловлена снижением уровня ингибитора апоптоза — sFas на 21-е сутки на фоне сдвига PDGF ВВ к исходному уровню. 2. Повышение содержания белка Вах в первые часы после операции на фоне роста PDGF BB на 7-е сутки при увеличенном количестве sFas на 21-е сутки и PDGF ВВ к концу 1-го месяца ведет к развитию рестеноза зоны вмешательства. </p></sec></abstract><trans-abstract xml:lang="en"><p>Restenosis of the reconstruction zone is one of the main postoperative complications of vascular reconstructions, which develops in 18–40% of cases and leads to an increase in the risk of limb loss to 20–25%. The search for new markers for predicting the development of this complication is an urgent problem today.</p><sec><title>Aim of study</title><p>Aim of study. To assess the dynamics of markers of apoptosis and cell proliferation at different times after endovascular intervention and their role in the development of restenosis of the reconstruction zone in patients with peripheral arterial disease (PAD).</p></sec><sec><title>Material and methods</title><p>Material and methods. The clinical study included 30 patients with PAD stage III disease. After further examination, the patients underwent endovascular intervention on the arteries of the femoral-popliteal segment. If restenosis developed, the patients were re-operated. In patients before surgery, within the first hour, and then on days 1, 7, 14, 21, 30 after the operation, venous blood was taken to determine the markers Bax, sFas, PDGF BB using enzyme immunoassay.</p></sec><sec><title>Results</title><p>Results. After endovascular intervention, the first wave of apoptosis was triggered with an increase in the amount of proapoptotic protein Bax (p=0,00003) from 1 to 24 hours, followed by a decrease by day 7 (p=0.0008) compared to the amount on day 1. The PDGF BB level increased from day 1 after surgery (p=0.03) with maximum values on day 7 (p=0.0002) compared to the level on day 1. Then the second wave was triggered with a peak decrease in the level of the apoptosis inhibitor sFas on day 21 (p=0.002). After 9-12 months, restenosis of the intervention zone with a return of limb ischemia developed in 10 patients. During the first hour (p=0.004) in patients with restenosis, the level of Bax protein was significantly increased, with an increase in the level of PDGF BB by day 7 (p=0.011), and sFas by day 21 (p=0.0001), PDGF BB by the end of 1 month (p=0.004) compared to values in patients without this complication.</p></sec><sec><title>Conclusion</title><p>Conclusion. 1. Endovascular intervention causes two waves of apoptosis in the postoperative period. The first wave is associated with an increase in Bax protein in the first hours, followed by an increase in PDGF BB on day 7. The second wave of apoptosis is due to a decrease in the inhibitor of apoptosis — sFas for 21 days against the background of the shift of the PDGF BB to the initial level. 2. An increase in Bax protein within the first hours after surgery in the course of PDGF BB growth on day 7 with an increased amount of sFas on day 21 leads and PDGF BB by the end of 1 month leads to the development of restenosis of the intervention area. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рестеноз</kwd><kwd>Вах</kwd><kwd>PDGF BB</kwd><kwd>sFas</kwd><kwd>атеросклероз артерий нижних конечностей</kwd></kwd-group><kwd-group xml:lang="en"><kwd>restenosis</kwd><kwd>Bax</kwd><kwd>PDGF BB</kwd><kwd>sFas</kwd><kwd>atherosclerosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gökgöl C, Diehm N, Räber L, Büchler P. Prediction of restenosis based on hemodynamical markers in revascularized femoro-popliteal arteries during leg flexion. Biomech Model Mechanobiol. 2019;18(6):1883–1893. PMID: 31197509 https://doi/org/10.1007/s10237-019-01183-9</mixed-citation><mixed-citation xml:lang="en">Gökgöl C, Diehm N, Räber L, Büchler P. Prediction of restenosis based on hemodynamical markers in revascularized femoro-popliteal arteries during leg flexion. Biomech Model Mechanobiol. 2019;18(6):1883–1893. PMID: 31197509 https://doi.org/10.1007/s10237-019-01183-9</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fang J, Pan Z, Guo X. Research advance of ANRIL on atherosclerosis by regulating cell proliferation and apoptosis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;25;49(1):113–117. PMID: 32621415</mixed-citation><mixed-citation xml:lang="en">Fang J, Pan Z, Guo X. Research advance of ANRIL on atherosclerosis by regulating cell proliferation and apoptosis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;25;49(1):113–117. PMID: 32621415</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rymer JA, Jones WS. Femoropopliteal In-Stent Restenosis. Circ Cardiovasc Interv. 2018;11(12):e007559. PMID: 30562092 https://doi/org/10.1161/CIRCINTERVENTIONS.118.007559</mixed-citation><mixed-citation xml:lang="en">Rymer JA, Jones WS. Femoropopliteal In-Stent Restenosis. Circ Cardiovasc Interv. 2018;11(12):e007559. PMID: 30562092 https://doi/org/10.1161/CIRCINTERVENTIONS.118.007559</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu ZR, He Q, Wu WB, Chang G, Yao C, Zhao Y, et al. MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease. J Atheroscler Thromb. 2018;25(11):1168– 1181. PMID: 29760303 https://doi/org/10.5551/jat.44024</mixed-citation><mixed-citation xml:lang="en">Zhu ZR, He Q, Wu WB, Chang G, Yao C, Zhao Y, et al. MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease. J Atheroscler Thromb. 2018;25(11):1168– 1181. PMID: 29760303 https://doi.org/10.5551/jat.44024</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Калинин Р.Е., Сучков И.А., Климентова Э.А., Егоров А.А. К вопросу о роли апоптоза в развитии атеросклероза и рестеноза зоны реконструкции. Новости хирургии. 2020;28(4):418–427. https://doi/org/10.18484/2305-0047.2020.4.418</mixed-citation><mixed-citation xml:lang="en">Kalinin RE, Suchkov IA, Klimentova EA, Egorov AA. To the Question of the Role of Apoptosis in the Development of Atherosclerosis and Restenosis of the Reconstruction Zone. Novosti khirurgii. 2020;28(4):418–427. (In Russ.) https://doi.org/10.18484/2305-0047.2020.4.418</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Калинин Р.Е., Сучков И.А., Климентова Э.А., Егоров А.А. Маркеры апоптоза и пролиферации клеток при воспалительно-фибропролиферативных заболеваниях сосудистой стенки (обзор). Современные технологии в медицине. 2020;12(4):119–128. https://doi/org/10.17691/stm2020.12.4.13</mixed-citation><mixed-citation xml:lang="en">Klimentova EA, Suchkov IA, Egorov AA, Kalinin RE. Apoptosis and Cell Proliferation Markers in Inflammatory-Fibroproliferative Diseases of the Vessel Wall (Review). Sovremennye tehnologii v medicine. 2020;12(4):119–128. https://doi.org/10.17691/stm2020.12.4.13</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther. 2004;4(1):33–39. PMID: 15032612 https://doi/org/10.2174/1566523044578022</mixed-citation><mixed-citation xml:lang="en">Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther. 2004;4(1):33–39. PMID: 15032612 https://doi.org/10.2174/1566523044578022/</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Su G, Sun G, Liu H, Shu L, Liang Z. Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels. 2018;33(10):1185–1194. PMID: 29704100 https://doi/org/10.1007/s00380-018-1169-7</mixed-citation><mixed-citation xml:lang="en">Su G, Sun G, Liu H, Shu L, Liang Z. Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels. 2018;33(10):1185–1194. PMID: 29704100. https://doi.org/10.1007/s00380-018-1169-7</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87(3):184–188. PMID: 10926867 https://doi/org/10.1161/01.res.87.3.184</mixed-citation><mixed-citation xml:lang="en">Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87(3):184–188. PMID: 10926867. https://doi.org/10.1161/01.res.87.3.184</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X, et al. Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFкB/mTOR/P70S6K signaling cascade. Redox Biol. 2018;14:656–668. PMID: 29175753 https://doi/org/10.1016/j.redox.2017.11.012</mixed-citation><mixed-citation xml:lang="en">Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X, et al. Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFкB/mTOR/P70S6K signaling cascade. Redox Biol. 2018;14:656–668. PMID: 29175753 https://doi.org/10.1016/j.redox.2017.11.012</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rutherford C, Martin W, Salame M, Carrier M, Anggård E, Ferns G. Substantial inhibition of neointimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis. 1997;130(1-2):45–51. PMID: 9126647 https://doi/org/10.1016/s0021- 9150(96)06042-x</mixed-citation><mixed-citation xml:lang="en">Rutherford C, Martin W, Salame M, Carrier M, Anggård E, Ferns G. Substantial inhibition of neointimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis. 1997;130(1-2):45–51. PMID: 9126647 https://doi.org/10.1016/s0021-9150(96)06042-x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Бокерия Л.А., Покровский А.В. (председатели экспертной группы). Национальные рекомендации по диагностике и лечению заболеванию артерий нижних конечностей. Москва; 2019. URL: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_ LLA_2019.pdf [Дата обращения 23 ноября 2021 г.]</mixed-citation><mixed-citation xml:lang="en">Bokeriya LA, Pokrovskiy AV. Natsional’nye rekomendatsii po diagnostike i lecheniyu zabolevaniyu arteriy nizhnikh konechnostey. Moscow; 2019. (in Russ.) Available at: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf [Accessed Nov 23, 2021]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Калинин Р.Е., Сучков И.А., Климентова Э.А., Егоров А.А., Поваров В.О. Апоптоз в сосудистой патологии: настоящее и будущее. Российский медико-биологический вестник имени академика И.П. Павлова. 2020;28(1):79–87. https://doi/org/10.23888/PAVLOVJ202028179- 87</mixed-citation><mixed-citation xml:lang="en">Kalinin RE, Suchkov IA, Klimentova ЕA, Egorov AA, Povarov VO. Apoptosis in vascular pathology: present and future. I.P. Pavlov Russian Medical Biological Herald. 2020;28(1):79–87. (in Russ.) https://doi.org/10.23888/PAVLOVJ202028179-87</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87(3):184–8. PMID: 10926867 https://doi/org/10.1161/01.res.87.3.184</mixed-citation><mixed-citation xml:lang="en">Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87(3):184–188. PMID: 10926867 https://doi.org/10.1161/01.res.87.3.184</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49(3):327–33. PMID: 6887785</mixed-citation><mixed-citation xml:lang="en">Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49(3):327–333. PMID: 6887785</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bochaton-Piallat M, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995;146(5):1059–1064. PMID: 7747800</mixed-citation><mixed-citation xml:lang="en">Bochaton-Piallat M, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995; 146(5):1059–1064. PMID: 7747800</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Katsaros KM, Wiesbauer F, Speidl WS, Kastl SP, Huber K, Zorn G, et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost. 2011;105(5):883–891. PMID: 21359408 https://doi/org/10.1160/TH10- 09-0566</mixed-citation><mixed-citation xml:lang="en">Katsaros KM, Wiesbauer F, Speidl WS, Kastl SP, Huber K, Zorn G, et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost. 2011;105(5):883–891. PMID: 21359408 https://doi.org/10.1160/TH10- 09-0566</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Стрельникова Е.А., Трушкина П.Ю., Суров И.Ю., Короткова Н.В., Мжванадзе Н.Д., Деев Р.В. Эндотелий in vivo и in vitro. Часть 1: Гистогенез, структура, цитофизиология и ключевые маркеры. Наука молодых (Eruditio Juvenium). 2019;7(3):450–465. https://doi/org/10.23888/HMJ201973450-465</mixed-citation><mixed-citation xml:lang="en">Strelnikova EA, Trushkina PYu, Surov IYu, Korotkova NV, Mzhvanadze ND, Deev RV. Endothelium in Vivo And in Vitro. Part 1: Histogenesis, Structure, Cytophysiology and Key Markers. Eruditio Juvenium. 2019;7(3):450–465. (in Russ). https://doi.org/10.23888/HMJ201973450-465</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guégan JP, Legembre P. Nonapoptotic functions of Fas/CD95 in the immune response. FEBS J. 2018;285(5):809–827. PMID: 29032605 https://doi.org/10.1111/febs.1429</mixed-citation><mixed-citation xml:lang="en">Guégan JP, Legembre P. Nonapoptotic functions of Fas/CD95 in the immune response. FEBS J. 2018;285(5):809–827. PMID: 29032605 https://doi.org/10.1111/febs.1429</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
